The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma

Autor: Rodriguez, J. (José), Conde, E. (Eulogio), Gutierrez, A. (Antonio), Lahuerta, J.J. (Juan José), Arranz, R. (R.), Sureda, A. (Anna), Zuazu, J. (Javier), Fernandez-de-Sevilla, A. (A.), Bendandi, M. (Maurizio), Solano, C. (C.), Leon, A. (Angel), Varela, M.R. (María Rosario), Caballero, M.D. (M.D.), Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO)
Jazyk: angličtina
Rok vydání: 2007
Předmět:
Zdroj: Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Popis: BACKGROUND AND OBJECTIVES: Preliminary data on the use of autologous stem cell transplantation (ASCT) as a salvage therapy for peripheral T-cell lymphoma (PTCL) indicate that the results are similar to those obtained in aggressive B-cell lymphomas. The aim of our study was to analyze outcomes of a large series of patients with PTCL with a prolonged follow-up who received ASCT as salvage therapy. DESIGN AND METHODS: Between 1990 and 2004, 123 patients in this situation were registered in the GELTAMO database. The median age at transplantation was 43.5 years; in 91% of patients the disease was chemosensitive. RESULTS: Seventy-three percent of the patients achieved complete remission, 11% partial remission and the procedure failed in 16%. At a median follow-up of 61 months, the 5-year overall and progression-free survival rates were 45% and 34%, respectively. The presence of more than one factor of the adjusted International Prognostic Index (a-IPI) and a high beta2-microglobulin at transplantation were identified as adverse prognostic factors for both overall and progression-free survival and allowed the population to be stratified into three distinct risk groups. INTERPRETATION AND CONCLUSIONS: Our data show that approximately one third of patients with PTCL in the salvage setting may enjoy prolonged survival following ASCT, provided they are transplanted in a chemosensitive disease state. The a-IPI and beta2-microglobulin level predict the outcome after ASCT in relapsing/refractory PTCL.
Databáze: OpenAIRE
Externí odkaz: